Served as interim CEO of NeoTherma, managing corporate structuring and an initial capital raise. Currently overseas and assists in implementation of corporate finance, structure and strategyNeoTherma Oncology (NTO) is developing the Vectron Thermal Oncology Treatment System in a manner consistent with evidence-based medicine principles to ensure both clinical, regulatory and market success. Our management team has decades of experience developing cutting edge technologies into innovative medical products in the US, EU and other important regulatory jurisdictions. We are in the process of efficiently developing, effectively clinically validating, and expecting to soon market therapies which represent a paradigm shift in treating serious cancers, providing hope and extended quality of life to cancer patients worldwide.NTO is a developmental stage therapeutic medical device company which is commercializing its disruptive Vectron Thermal Treatment System for use as adjuvant therapy for deep solid tumors. Vectron noninvasively applies a safe, non-ionizing electromagnetic field to produce ‘fever-range’ temperatures ('Mild Hyperthermia'or mHT) inside tumor tissue, increasing the effectiveness of anticancer radio-, chemo- and immuno- therapy. mHT acts by reversing the hypoxia known to make tumors resistant to radiation therapy, delivering higher concentrations of chemo-therapeutic drugs via enhanced blood perfusion, and most significantly in the era of checkpoint inhibitors, by promoting each patient’s own curative immune response. NTO’s pipeline first focuses on pancreatic ductal adenocarcinoma, followed by squamous cell carcinoma of the head and neck, and then an array of deep solid tumors to be prioritized in collaboration with our pharma strategic partners.

President of Premier Management assisting clients in restructuring and repositioning of assets, tax hearings, and debt restructuring. Managed operations including accounting, software implementation, marketing, asset management, and communications.